| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7462645 | MYLAN SPECLT | Bronchodilating beta-agonist compositions and methods |
Jun, 2021
(2 years ago) | |
| US9730890 | MYLAN SPECLT | Bronchodilating beta-agonist compositions and methods |
Jun, 2021
(2 years ago) | |
| US6814953 | MYLAN SPECLT | Bronchodilating compositions and methods |
Jun, 2021
(2 years ago) | |
| US8623922 | MYLAN SPECLT | Bronchodilating Beta-agonist compositions and methods |
Jun, 2021
(2 years ago) | |
| US7348362 | MYLAN SPECLT | Bronchodilating β-agonist compositions and methods |
Jun, 2021
(2 years ago) | |
| US6667344 | MYLAN SPECLT | Bronchodilating compositions and methods |
Jun, 2021
(2 years ago) | |
Perforomist is owned by Mylan Speclt.
Perforomist contains Formoterol Fumarate.
Perforomist has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Perforomist are:
- US7462645
- US9730890
- US6814953
- US8623922
- US7348362
- US6667344
Perforomist was authorised for market use on 11 May, 2007.
Perforomist is available in solution;inhalation dosage forms.
Perforomist can be used as maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd).
The generics of Perforomist are possible to be released after 22 June, 2021.
Drugs and Companies using FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 11 May, 2007
Treatment: Maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION
PERFOROMIST family patents
